3.8 Meeting Abstract

Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamide followed by docetaxel +/- capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study GeparQuattro

Journal

EJC SUPPLEMENTS
Volume 6, Issue 7, Pages 47-47

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S1359-6349(08)70313-6

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available